Clinical Trial Update: A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating ABSK043 in combination with Glecirasib for non-small cell lung cancer is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ABSK043 (ABSK043)
• Glecirasib

Snippet

Sponsor: Abbisko Therapeutics Co, Ltd | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING